Voronoi, Inc. (310210.KQ)
KOSDAQ · KRW · Healthcare · Biotechnology
₩118,800 (-2.86%) as of
Key statistics
- Market cap
- 2.18T
- Forward P/E
- -33.45
- Dividend yield
- 0.00%
- 52-week range
- 97,500.00 – 375,500.00
- Beta
- 1.56
- Revenue (TTM)
- 4.16B
- Profit margin
- 0.00%
- Analyst target
- ₩340,000
- Volume
- 73.48k
About Voronoi, Inc.
Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company's products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multiple sclerosis and amyotrophic lateral sclerosis; VRN13 to treat pulmonary arterial hypertension; and VRN14 for the treatment of refractory solid cancer. Voronoi, Inc. was incorporated in 2015 and is based in Incheon, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Incheon, South Korea
- Employees
- 169
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.